



RECEIVED

JAN 22 2001

Response Under 37 C.F.R. § 1.600/2900

Expedited Procedure-

Examining Group 1625


Attorney's Docket No. N0260/7031 (ERG)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Nigel L. Webb, et al.  
Serial No. : 09/265,307  
Filing Date : March 9, 1999  
For : FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF  
Examiner : B. Trinh  
Art Group : 1625

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Box RCE, Commissioner for Patents, Washington, D.C. 20231, on the 22nd day of October, 2001.

  
Edward R. Gates

Box RCE  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

**AMENDMENT**

A three month extension of time, from July 20, 2001 to October 20, 2001, is requested for response to the final Office Action mailed from the Patent Office on April 20, 2001.

In the Claims:

1. (amended) A fatty acid-anticancer compound conjugate composition for administration to a subject, comprising at least one fatty acid-anticancer compound conjugate in a container for administration to a subject, wherein the amount of the fatty acid-anticancer compound in the container is at least about 10% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound, wherein the container is a container for intravenous administration.

Please add the following claims: